The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 08, 2011
Filed:
Jul. 16, 2008
Michael James Rishel, Rensselaer, NY (US);
Bruce Fletcher Johnson, Scotia, NY (US);
Kande Kankanamalage Dayarathna Amarasinghe, Latham, NY (US);
Sean Richard Dinn, Delmar, NY (US);
Michael James Rishel, Rensselaer, NY (US);
Bruce Fletcher Johnson, Scotia, NY (US);
Kande Kankanamalage Dayarathna Amarasinghe, Latham, NY (US);
Sean Richard Dinn, Delmar, NY (US);
General Electric Company, Niskayuna, NY (US);
Abstract
The present invention provides novel alpha-fluoroalkyl dihydrotetrabenazine compounds I wherein Ris a C-Cfluorinated aliphatic radical; Ris hydrogen or a C-Caliphatic radical; Ris hydrogen or a C-Caliphatic radical; and Ris a C-Caliphatic radical, a C-Ccycloaliphatic radical, or a C-Caromatic radical. The alpha-fluoroalkyl dihydrotetrabenazine compounds are provided in both racemic and enantiomerically enriched forms and may comprise either or both of fluorine-18 and fluorine 19. The alpha-fluoroalkyl dihydrotetrabenazine compounds are believed to possess high affinity for VMAT-2, a biomarker implicated in human diabetes. The alpha-fluoroalkyl dihydrotetrabenazine compounds comprising a fluorine-18 group are useful as PET imaging agents targeting the VMAT-2 biomarker. The non-radiolabled alpha-fluoroalkyl dihydrotetrabenazine compounds are useful as probes for the discovery of PET imaging agents.